ArticleKidney3602026
Biopsychosocial Correlates of Somatic Symptom Burden in CKD: Results of the Hamburg City Health Study.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
key pointsKidney function (GFR) correlated with somatic symptom burden bivariately, but not in the multiple regression model. Female sex, coronary heart disease, self-reported general health, proneness to illness, and depressive symptoms correlated with symptom burden. Similar biopsychosocial correlates of symptom burden were observed in individuals with CKD, coronary heart disease, and controls.
backgroundPersistent somatic symptoms in individuals with CKD occur across all stages and affect patients' quality of life, morbidity, and mortality. We aimed to unravel associations between biopsychosocial factors and symptom burden in individuals with CKD.
methodsThis cross-sectional study analyzed individuals with CKD (eGFR <60 ml/min per 1.73 m 2 ) from the first 10,000 participants of the population-based Hamburg City Health Study. Somatic symptom burden (Patient Health Questionnaire-15) was the primary outcome. Its association with potential biologic ( e.g ., eGFR), psychologic ( e.g ., depressive symptoms), and sociodemographic correlates was analyzed in a multivariate prediction model. Correlates were compared with healthy controls and individuals with coronary heart disease (CHD).
resultsSomatic symptom burden in patients with non-dialysis CKD ( n =582, mean age: 69.58 years; 44.7% women; mean baseline eGFR: 52 ml/min per 1.73 m 2 ) increased with lower eGFR ( r =-0.161, P < 0.001). However, in a stepwise multiple linear regression model, eGFR was not correlated with symptom burden. By contrast, female sex, CHD, self-reported general health, proneness to illness, and depressive symptoms were associated with somatic symptom burden. Correlates of somatic symptom burden were compared with those in patients with CHD ( n =618, mean age: 67.13 years; 24.1% women; mean baseline eGFR: 81 ml/min per 1.73 m 2 ) and matched healthy controls ( n =582, mean age: 69.58 years; 44.7% women; mean baseline eGFR: 81 ml/min per 1.73 m 2 ). Self-reported general health and depression were associated with somatic symptom burden in all groups, while there were specific correlates in the CHD ( e.g ., age) and the healthy control group ( e.g ., expectancy of deterioration of health status).
conclusionsSomatic symptom burden in CKD was only marginally related to the eGFR but rather to biopsychosocial factors. Therefore, taking a biopsychosocial perspective on persistent somatic symptom in CKD is important. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Biopsychosocial correlates of somatic symptom burden in patients with CKD from the Hamburg City Health Study, 10.17605/OSF.IO/58S2R.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.